Compare PLSE & OPCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | OPCH |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.5B |
| IPO Year | 2015 | 1996 |
| Metric | PLSE | OPCH |
|---|---|---|
| Price | $55.42 | $23.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $22.00 | ★ $36.57 |
| AVG Volume (30 Days) | 578.9K | ★ 1.6M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.25 |
| EPS | N/A | ★ 0.29 |
| Revenue | N/A | ★ $4,998,202,000.00 |
| Revenue This Year | $840.00 | $7.21 |
| Revenue Next Year | $287.54 | $8.55 |
| P/E Ratio | ★ N/A | $80.97 |
| Revenue Growth | N/A | ★ 16.17 |
| 52 Week Low | $12.56 | $18.01 |
| 52 Week High | $58.90 | $36.80 |
| Indicator | PLSE | OPCH |
|---|---|---|
| Relative Strength Index (RSI) | 65.31 | 55.94 |
| Support Level | $15.64 | $22.97 |
| Resistance Level | N/A | $24.70 |
| Average True Range (ATR) | 4.08 | 0.46 |
| MACD | -0.25 | -0.07 |
| Stochastic Oscillator | 60.56 | 67.39 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.